



Stereoselective total synthesis of (\pm)-homochelidonine

Makoto Yoshida, Toshiko Watanabe and Tsutomu Ishikawa*


Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi, Inage, Chiba 263-8522, Japan

Received 4 July 2002; accepted 19 July 2002

Abstract—(\pm)-Homochelidonine, a B/C-*cis*-11-hydroxyhexahydrobenzo[*c*]phenanthridine alkaloid, was stereoselectively synthesized from arnottin II, a non-alkaloidal spiro lactonol tetralone which had been structurally correlated to chelerythrine, a fully aromatized-type alkaloid, by the common use of a 2-benzofuranyl-1-tetralone as a synthetic key intermediate. Thus, a valuable synthetic method accessible to benzo[*c*]phenanthridine alkaloids with different oxidation stages of the basic skeleton could be proposed. © 2002 Elsevier Science Ltd. All rights reserved.


Benzo[*c*]phenanthridine alkaloids¹ showing interesting biological activities can be classified into two main categories of a B/C-*cis*-11-hydroxyhexahydro-type (a partially hydrogenated-type) and a fully aromatized-type alkaloid based on the oxidation stage of a basic skeleton;² e.g. homochelidonine (**1**) as the former and chelerythrine (**2**) as the latter. Various types of synthetic methods have been reported for the construction of the benzo[*c*]phenanthridine skeleton;² however, only limited approaches have appeared on a partially hydrogenated-type.³ We had already succeeded in establishing a general and practical synthetic method⁴ for the fully aromatized-type alkaloids including **2**⁵ through 2-aryl-1-tetralones as key intermediates in the process of the examination of structure–activity relationship against tumor cells. On the other hand, for the structural determination of a naturally-occurring non-alkaloidal arnottin II (**3**) coexisting with benzo[*c*]phenanthridine alkaloids, its synthesis had been also achieved using 2-benzofuranyl-1-tetralone (**4**) as a key synthetic intermediate of **2**.⁶ The presence of a unique 2-spirolactonol-3,4-dehydro-1-tetralone moiety in arnottin II (**3**) prompted us to undertake synthesis of homochelidonine (**1**) by the chemical conversion of **3**. In this paper we present the stereoselective total synthesis of (\pm)-homochelidonine (**1**) from arnottin II (**3**), leading to synthetic correlation between partially hydrogenated-type and fully aromatized-type benzo[*c*]phenanthridine alkaloids.

The retrosynthetic analysis is shown in Scheme 1, in which a hexahydrobenzo[*c*]phenanthridine skeleton **5** with all *cis* relation of the hetero atom functions on the



C ring and an 1,2,3,4-tetrahydro-1-naphthylamine derivative **6** with a spiro lactone moiety are planned to be key intermediates.

Oxidation of **3** with a stoichiometric amount of OsO₄⁷ afforded a *cis*-diol **7** due to approach of the reagent from the less hindered site. Introduction of a nitrogen function at the 1 position of **7** was carried out by treatment with hydroxylamine after protection of the glycol function as an acetonide to give an oxime **9**.




Scheme 1.

* Corresponding author. Tel./fax: +81-43-290-2910; e-mail: bentii@p.chiba-u.ac.jp

Reduction of **9** with NaBH_3CN in the presence of TiCl_3 ⁸ successfully provided an amine **6** as the desired single stereoisomer. Reductive cleavage of the spiro-lactone ring in **6** with LiAlH_4 followed by cyclization under the Mitsunobu reaction conditions after conversion of the reduction product **10** into a trifluoroacetamide derivative **11** gave a 10*b*,11,12-trioxygenated hexahydrobenzo[*c*]phenanthridine skeleton **12**. All *cis* relation among the hetero atom substituents on the C ring system of **12** was determined by NOE enhancements in NMR experiments.

Hydrolysis of the amide function of **12** followed by treatment with Boc_2O afforded an unexpected cyclic carbamate **14** quantitatively. This fact unambiguously



Scheme 2. (a) (i) OsO_4 , pyridine, rt, 1 h; (ii) NaHSO_3 aq., rt, 20 h; (b) $(\text{CH}_3)_2\text{C}(\text{OCH}_3)_2$, *p*- $\text{TsOH}\cdot\text{H}_2\text{O}$, DMF, 90°C, 1 h; (c) $\text{NH}_2\text{OH}\cdot\text{HCl}$, pyridine, 100°C, 6 h; (d) TiCl_3 aq., NaBH_3CN , NH_4OAc , dioxane, rt, 5 h; (e) LiAlH_4 , THF, rt, 1 h; (f) (i) $(\text{CF}_3\text{CO})_2\text{O}$, pyridine, 0°C, 2 h; (ii) NaHCO_3 aq., MeOH, rt, 16 h; (g) DEAD, Ph_3P , THF, rt, 3 h; (h) NaOH aq., MeOH, rt, 24 h; (i) Boc_2O , DMAP, CH_3CN , 60°C, 2 h; (j) H_2 , 20% $\text{Pd}(\text{OH})_2/\text{C}$, HCHO aq., HCOOH , MeOH, rt, 24 h; (k) CF_3COOH , CH_2Cl_2 , rt, 20 h; (l) thiocarbonyldiimidazole, $(\text{CH}_2\text{Cl})_2$, reflux, 3 h; (m) Bu_3SnH , AIBN, toluene, reflux, 3 h.

indicated the *cis*-orientation between the 4*b*-amine function and the 10*b*-hydroxyl group. It was found that selective deoxygenation of the 10*b*-oxygen function and reductive *N*-methylation concomitantly occurred when the cyclic carbamate **14** was treated with 20% $\text{Pd}(\text{OH})_2/\text{C}$ under hydrogen atmosphere in the presence of formaldehyde, to directly give an 11,12-dioxygenated hexahydro-*N*-methylbenzo[*c*]phenanthridine skeleton **5** with all *cis*-oriented hydrogen atoms on the C ring. Interestingly, reductive inversion at the 10*b*-position by displacement of an oxygen function to a hydrogen atom was observed in this reduction, resulting in the formation of a product with the desired stereochemistry. After deprotection of the acetal function in **5** followed by thiocarbamation, treatment of the thiocarbamate **16** under radical conditions using Bu_3SnH^9 smoothly afforded the expected homochelidonine (**1**), which was identical with an authentic sample^{3b} (Scheme 2). The overall yield of **1** from **3** was 11% in 15 steps.

In conclusion, (\pm)-homochelidonine (**1**) was stereoselectively synthesized from arnottin II (**3**) through three key steps of (i) the introduction of oxygen functions to the 11 and 12 positions, (ii) reduction of the oxime group, and (iii) hydrogenolysis of the 10*b*-hydroxyl group. It should be noted that synthetic correlation among homochelidonine (**1**) (a partially hydrogenated-type alkaloid), chelerythrine (**2**) (a fully aromatized-type alkaloid), and arnottin II (**3**) (a non-alkaloidal spiro-lactone) in the use of the 2-benzofuran-1-tetralone (**4**) as a common key intermediate could propose a valuable synthetic method accessible to both types of alkaloids. Presently, optimization of each step and trials for application to asymmetric synthesis are under investigation.

Acknowledgements

We thank Professor T. Naito of Kobe Pharmaceutical University for a generous gift of the authentic sample of homochelidonine.

References

- Simanek, V. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: New York, 1983; Vol. 26, p. 185.
- Ishikawa, T.; Ishii, H. *Heterocycles* **1999**, *50*, 627–639.
- For example: (a) Oppolzer, W.; Keller, K. *J. Am. Chem. Soc.* **1971**, *93*, 3836–3837; (b) Ninomiya, I.; Yamamoto, O.; Naito, T. *J. Chem. Soc., Perkin Trans. 1* **1983**, 2171–2174.
- (a) Ishii, H.; Ichikawa, Y.-I.; Kawanabe, E.; Ishikawa, M.; Ishikawa, T.; Kuretani, K.; Inomata, M.; Hoshi, A. *Chem. Pharm. Bull.* **1985**, *33*, 4139–4151; (b) Ishii, H.; Chen, I.-S.; Ishikawa, T. *J. Chem. Soc., Perkin Trans. 1* **1987**, 671–678; (c) Ishii, H.; Chen, I.-S.; Ueki, S.; Akaike, M.; Ishikawa, T. *Chem. Pharm. Bull.* **1987**, *35*, 2717–2725.

5. (a) Ishii, H.; Ishikawa, T.; Takeda, S.; Suzuki, M.; Harayama, T. *Chem. Pharm. Bull.* **1992**, *40*, 2002–2006; (b) Ishikawa, T.; Takami, A.; Abe, M.; Chen, I.-S.; Harayama, T.; Ishii, H. *Chem. Pharm. Bull.* **1995**, *43*, 766–770.
6. Ishikawa, T.; Murota, M.; Watanabe, T.; Harayama, T.; Ishii, H. *Tetrahedron Lett.* **1995**, *36*, 4269–4272.
7. The use of a catalytic amount of the reagent was not successful.
8. Leeds, J. P.; Kirst, H. A. *Synth. Commun.* **1988**, *18*, 777–782.
9. Mills, S.; Desmond, R.; Reamer, L. A.; Volante, R. P.; Shinkai, I. *Tetrahedron Lett.* **1988**, *29*, 281–284.